Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merrion Pharmaceuticals has executed an oral drug delivery Feasibility and Option agreement with a pharmaceutical company.
Subscribe to our email newsletter
The agreement will evaluate the ability of Merrion Pharma’s patented GIPET technology to boost the bioavailablity of three of the ‘big pharma’ company’s compounds.
Following the feasibility studies, the company will have the option to enter into a licensing agreement for Merrion’s GIPET technology.
Merrion Pharma claims that its GIPET technology is a platform technology with broad applicability which covers a range of compounds with varying physiochemical properties and molecular weights.
Merrion Pharma’s patented drug delivery technology GIPET is supported by a large database reflecting 10 years research and development by drug delivery experts and 21 clinical studies conducted on a broad range of drug types.
GIPET has shown the ability to improve absorption by as much as 200 times, achieving intersubject reproducibility and with a positive safety database, the company said.
Merrion Pharma CEO John Lynch said they are very pleased to be entering into this agreement to assess the ability of their GIPET technology to substantially improve the product profile of three of their compounds.